In 2010 Clinuvel commenced its vitiligo program to evaluate the use of its first-in-class drug SCENESSE® (afamelanotide 16mg) as a repigmentation therapy in adults with generalised vitiligo.
The first of these studies, CUV102, has completed, with treatment results released in December 2012. A further trial, CUV103, commenced in Singapore in 2014. Read more about the CUV103 study in the announcement here.
Clinuvel has established this webpage to serve as a portal for all information relevant to this study and vitiligo more broadly. See this document for more details on participating in Clinuvel's vitiligo program.